Transformation of nanoparticles into hydrogels for long-acting and sensitized apoptosis therapy of triple negative breast cancer

studies confirmed enhanced apoptosis through dual-drug synergy with minimal systemic toxicity. This dynamic switching strategy delivery offers an innovative platform for protein-small molecule co-therapy, addressing TNBC resistance, and holds translational potential for clinical applications.